Strategic Collaborations Aptamer Group actively pursues funded research programs with Imperial College London and partners such as Radiopharmium, signaling readiness to engage in contract R&D, co-development, and sponsored projects that can be monetized through collaborative engagements.

Diagnostics Testing The ongoing rapid testing initiatives for folic acid in fortified foods and related pathogen detection work point to strong demand for rapid binder driven diagnostics; sales opportunities include platform partnerships, assay development services, and turnkey diagnostic kits.

Radiopharmaceutical Potential The radiopharmaceutical programme with Radiopharmium indicates interest in using Optimer binders for targeted therapies, presenting opportunities to supply binders, co-develop radiopharmaceutical solutions, or partner with CROs and pharma companies in nuclear medicine.

Licensing Enablement Licensing activity with Alphazyme demonstrates a viable model for monetizing Optimer binders in molecular biology tools; you can target biotech instrument and reagent vendors seeking advanced binders for PCR workflows and related applications.

Growth Partnerships With a lean team and recent fundraising, Aptamer Group appears poised for early stage partnerships, contract research, and technology licensing in the UK and EU life sciences ecosystem; ideal targets include biotech firms, diagnostic developers, food safety labs, and environmental testing providers.